MetaCap

Tenax Therapeutics (TENX) vs vTv Therapeutics (VTVT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

vTv Therapeutics (VTVT) has outperformed Tenax Therapeutics (TENX) over the past year, losing 47.5% versus a loss of 84.7%. Over five years, VTVT leads with a -71.1% price change compared with -99.9% for TENX. vTv Therapeutics is the larger company by market cap ($62.2 million vs $56.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TENX-84.66%VTVT-47.53%
+135%+20%-95%
Nov 21, 20251 yearNov 20, 2026
TENX-99.94%VTVT-72.69%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TENX versus VTVT key metrics
MetricTENXVTVT
Share price$1.25$15.51
Market cap$56.92M$62.22M
1-day change-10.07%-5.20%
YTD return-89.75%-61.22%
1-year return-84.66%-47.53%
5-year return-99.94%-71.06%
EPS (TTM)$-1.39$-0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-52.60M$-26.97M
52-week high$19.40$44.00
52-week low$1.24$15.47
Distance from 52-week high-93.56%-64.75%
Analyst consensusnonestrong_buy
Avg. price target upside+904.80%+261.06%
Average volume3.15M33.07K
Shares outstanding45.54M4.01M
Employees1426
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VTVT has outperformed TENX by 37.1 percentage points over the past year.

About Tenax Therapeutics

TENX stock →

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About vTv Therapeutics

VTVT stock →

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees

TENX vs VTVT FAQ

Which is bigger, Tenax Therapeutics or vTv Therapeutics?

vTv Therapeutics (VTVT) is larger, with a market capitalization of $62.22M compared with $56.92M for Tenax Therapeutics (TENX).

Which stock has performed better over the past year, TENX or VTVT?

VTVT returned -47.53% over the past 12 months, compared with -84.66% for TENX (price return, excluding dividends). Past performance does not predict future results.

Are Tenax Therapeutics and vTv Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons